This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Alkermes’ fumarate prodrug patent upheld by EPO despite legalchallenges

( May 15, 2025, 09:18 GMT | Official Statement) -- MLex Summary: The Boards of Appeal of the European Patent Office upheld Alkermes' patent on fumarate prodrugs for treating neurological diseases, including multiple sclerosis, after challenges by Teva, Hexal and Generics. Opponents argued the claims added subject matter, lacked novelty and inventive step, and weren't sufficiently disclosed. The appeal body rejected these arguments, as they found valid amendments, sufficient disclosure, and invention. The appeal was dismissed, and the patent was maintained in amended form per the Opposition Division’s earlier decision.The decision is attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections